<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944424</url>
  </required_header>
  <id_info>
    <org_study_id>RAC # 2091-009</org_study_id>
    <nct_id>NCT00944424</nct_id>
  </id_info>
  <brief_title>Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca</brief_title>
  <acronym>GORG-002</acronym>
  <official_title>GORG - 002 Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized phase III trial to determine the effectiveness of High dose versus Standard dose
      of Vitamin D2 (Ergocalciferol) given with Docetaxel in patients with metastatic breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 Arms Randomization in patients with metastatic breast cancer.

      Arm A = Docetaxel + High dose Vitamin D2

      Arm B = Docetaxel + Standard dose Vitamin D2
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression is from the start of Docetaxel to disease progression. Patients who have not progressed at the time of study completion or who are lost to follow-up are censored at the last Vitamin D administration date.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival is defined as the time from start of Docetaxel to death due to any cause. Patients for whom no death is captured on the clinical database are censored at the last date they were known to be alive.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A = Docetaxel + High dose Vitamin D2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel + Standard dose Vitamin D2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + High dose Vitamin D2</intervention_name>
    <description>Docetaxel + High dose Vitamin D2</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + Standard dose Vitamin D2</intervention_name>
    <description>Docetaxel + Standard dose Vitamin D2</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven metastatic adenocarcinoma of the breast.

          -  Gender: female.

          -  Age ≥18 years.

          -  ECOG performance status ≤ 2.(see appendix I)

          -  25 (OH) Vitamin D level ≤ 100nmol/L (40ng/L).

          -  No more than 1 prior chemotherapy regimen not including Docetaxel or Paclitaxel for
             metastatic breast cancer.

          -  Patients progressed on Doxorubicin or epirubicin as first line for metastatic breast
             cancer is eligible.

          -  Concurrent bisphosphonate therapy allowed.

          -  Life expectancy more than 6 months

          -  At least 12 months since prior adjuvant or neo-adjuvant chemotherapy including Taxanes
             regimens.

          -  Adequate hematologic, hepatic and renal function.

          -  Written informed consent.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Male breast cancer.

          -  Women of childbearing potential unless surgically sterile or using adequate measures
             of contraception.

          -  Metastatic inflammatory breast cancer.

          -  CNS metastasis.

          -  Leptomeningeal carcinomatosis.

          -  Malignant hypercalcemia.

          -  History of kidney stones.

          -  History of active primary hyperparathyroidism.

          -  Normal 25 (OH) Vitamin D level ≥100 nmol/L or ≥ 40 ng/L.

          -  Previous or concomitant malignancy of any type, except adequately treated basal cell
             carcinoma of the skin or in situ cervix cancer.

          -  Patient on any anti-Psychotic medications or Steroid therapy.

          -  History of malabsorption syndrome (pancreatic insufficiency, celiac disease and
             tropical sprue).

          -  Any of the following abnormal baseline hematological values:

               -  ANC &lt; 1.0 x109/L, or platelets &lt; 100.000 x 109/L.

          -  Any of the following abnormal laboratory tests: total serum bilirubin &gt;2.00 x ULN
             (upper limit of normal), AST, ALT &gt; 2.5 x ULN or ALP &gt;2.50 x ULN (upper limit of
             normal).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taher Al-Tweigeri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KFSHRC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dahish Ajarim, MD</last_name>
    <role>Study Director</role>
    <affiliation>KFSHRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taher Tweigeri, MD</last_name>
    <phone>0096614647272</phone>
    <phone_ext>38047</phone_ext>
    <email>ttwegieri@kfshrc.edu.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romelia Retuta</last_name>
    <phone>966-1-4647272</phone>
    <phone_ext>32957</phone_ext>
    <email>romelia@kfshrc.edu.sa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kuwait Cancer Center</name>
      <address>
        <city>Kuwait City</city>
        <country>Kuwait</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Center</name>
      <address>
        <city>Riyadh</city>
        <state>Central</state>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Taher Al-Tweigeri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dahish Ajarim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adher Al-Sayed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Al-Shabanah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Hospital and Oncology Center</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tarek Darwish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Fahad Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tawam Hospital</name>
      <address>
        <city>Al Ain City</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Kuwait</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>December 11, 2011</last_update_submitted>
  <last_update_submitted_qc>December 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D in patients with metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

